基本信息:
- 专利标题： TROGOCYTOSIS-MEDIATED THERAPY USING CD38 ANTIBODIES
- 申请号：PCT/EP2019/069035 申请日：2019-07-15
- 公开(公告)号：WO2020012038A1 公开(公告)日：2020-01-16
- 发明人： DE GOEIJ, Bart,E,C,G , ANDRINGA, Grietje , BEURSKENS, Frank , SCHUURMAN, Janine , SATIJN, David , AHMADI, Tahamtan
- 申请人： GENMAB A/S
- 申请人地址： Kalvebod Brygge 43 1560 Copenhagen V DK
- 专利权人： GENMAB A/S
- 当前专利权人： GENMAB A/S
- 当前专利权人地址： Kalvebod Brygge 43 1560 Copenhagen V DK
- 代理机构： GENMAB A/S
- 优先权： US62/697,719 20180713; US62/848,861 20190516
- 主分类号： C07K16/00
- IPC分类号： C07K16/00 ; C07K16/28 ; C07K16/36 ; A61K39/00
摘要：
Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.